reason report
bottom line announc financi result afternoon
provid pipelin updat includ increment chang
timelin updat call includ initi phase data
neuroendocrin gastrointestin
stromal tumor expect vs previous
initi phase data advanc
solid tumor expect vs previous also
provid clarif initi data
b-cell malign would present vs previous
overal continu view leader promis bispecif
space view compani plug-and-play antibodi platform
import long-term valu driver potenti sourc busi
develop opportun futur compani enter
numer technolog licens agreement repres valid
platform near-term cash flow compani view
well-posit execut long-term strategi strong
manag team financi posit reiter op
upcom catalyst mileston includ initi phase
data b-cell malign
ind applic bispecif partner
genentech initi phase data
neuroendocrin gastrointestin stromal tumor
initi data tumor microenviron tme
bispecif platform data phase studi
advanc solid tumor
continu guid toward cash suffici fund
oper beyond end cash
cash equival expect end approxim
cash equival chang vs previou
updat model financi result price target increas
result incorpor probability-adjust
mileston reflect recent partnership
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut gaap ep
pleas refer page import disclosur price chart analyst certif
clinical-stag biotechnolog compani develop engin antibodi treat
autoimmun allerg diseas cancer indic plug-and-play
antibodi platform gener deep pipelin consist advanc stage proprietari
program earli stage partner proprietari bispecif antibodi deep
pipelin earli stage bispecif antibodi program expect multipl clinic
readout view bispecif antibodi promis drug class view
bispecif platform import long-term valu driver compani potenti
sourc busi develop opportun futur addit enter
numer technolog licens agreement repres valid platform well
near-term cash flow compani view well-posit execut long-
term strategi strong manag team financi posit
price target base blend revenu multipl analysi
dcf analysi assign valu probability-weight sale royalti
probabl success diseas probability-weight sale royalti
probabl success acut myeloid leukemia probability-weight sale
royalti probabl success lymphoma probability-weight
royalti probabl success multipl myeloma probability-weight
royalti probabl success complement-medi diseas
probability-weight royalti probabl success lymphoma use
discount rate termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
collabor licens revenu
total incom expens
sti
svb leerink estim compani file
chang
oper
chang wc
invest
financ
svb leerink estim compani file
pipelin upcom event
approv launch us eu japan
svb leerink compani file
file accept us
royalti sale npv mm
